Biochemically Recurrent Prostate Cancer: Superior Agents to Conventional Imaging - Andrei Iagaru

Dr. Andrei Iagaru states that the significantly changing landscape of prostate cancer diagnoses is due to new and improved imaging agents and access to resources that were once available only outside of the United State.  In this particular study, 68GA-RM2, formerly known as 68Ga-Bombesin or BAY86-7548 PET/MRI was compared to conventional imaging for patients with biochemically recurring prostate cancer. Dr. Iagaru shares specific patient outcomes that demonstrate that 68GA-RM2 is superior to other agents in diagnosing and treating the disease. 

Biography:
Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine, Chief, Division of Nuclear Medicine and Molecular Imaging, Director, Nuclear Medicine Residency Program, Co-Director, PET-MRI Research Program, Stanford University, Stanford, California, USA

Related Content:

Role of MRI in Men on Active Surveillance - Laurence Klotz

A Phase II Study of 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer

Metabolically-stabilized 68Ga-NOTA-bombesin for PET Imaging of prostate cancer and influence of protease inhibitor Phosphoramidon.

Radiopharmaceuticals for diagnosis and therapy of neuroendocrine differentiated prostate cancer.